Navigation Links
SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR

DUBLIN, Calif., April 04, 2007 /PRNewswire-FirstCall/ -- SuperGen Inc. announced today that it will have multiple presentations at the American Association for Cancer Research Annual Meeting on April 14-18 in Los Angeles. These presentations will focus on data concerning many of SuperGen's current oncology programs including its lead tyrosine kinase inhibitor compound, MP470 and its ability to block Rad51, a key protein target involved in cancer cell drug resistance. Presentations will take place in the exhibit hall of the Los Angeles Convention Center.

    The schedule of SuperGen's presentations is:


    Date     Time (PDT)           Title                       Number/Section

    Sunday,   1 p.m. - 5 p.m.     Hydrochloride salt of       #1540

    April                         MP470, a potent

    15                            suppressor of Rad51,        Poster

                                  improves                    Section 31

                                  bioavailability and


    Monday,   8 a.m. - 12 p.m.    Discovery and               #2380

    April                         characterization of a

    16                            series of Axl kinase        Poster

                                  inhibitors using the        Section 30

                                  CLIMB(TM) process

    Monday,   8 a.m. - 12 p.m.    Discovery and               #2387

    April                         characterization of

    16                            small molecule              Poster

                                  inhibitors for Jak2         Section 30

    Monday,   8 a.m. - 12 p.m.    Zebrafish as a model        #2229

    April                         mechanistic screen

    16                            for small molecule          Poster

                                  inhibitors of DNMT1         Section 23

    Monday,   1 p.m. - 5 p.m.     Discovery and               #3261

    April                         development of MP529,

    16                            a new effective and         Poster

                                  selective inhibitor         Section 29

                                  of Aurora A kinase

    Tuesday,  8 a.m. - 12 p.m.    MP470, a potent             #4028

    April                         suppressor of Rad51,

    17                            improves response to        Poster

                                  platinum-based              Section 29

                                  anticancer agents

    Tuesday,  10:40 a.m. -        Novel DNA                   #4142

    April     10:55 a.m.          hypomethylating

    17                            agents: non-                Minisymposium

                                  nucleoside compounds        Cancer

                                  that do not                 Epigenetics

                                  incorporate into DNA

                                  selectively induce          Room 304 A-C

                                  degradation of DNA

                                  methyltransferase I

                                  (DNMT1) in human

                                  cancer cells by the

                                  proteasomal pathway

                                  and re-express

                                  silenced tumor

                                  suppressor genes

    Wed.,    8 a.m. - 12 p.m.     Dual inhibition of          #5421

    April                         receptor tyrosine

    18                            kinases of PDGFR and        Poster

                                  EGFR abolishes              Section 20

                                  prostate cancer cell

                                  growth in culture and

                                  in a mouse xenograft

                    model by complete

                                  dephosphorylation of


    About SuperGen

Based in Dublin, Calif., SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on inhibitors of aurora-A, tyrosine kinase and DNA methyltransferase. For more information about SuperGen, please visit

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.


    SuperGen                                Noonan Russo

    Timothy L. Enns                         Greg Geissman

    S.V.P., Corporate Communications        Director of Media Relations

& Business Development

    (925) 560-0100 x111                     (619) 814-3510


CONTACT: Timothy L. Enns, S.V.P., Corporate Communications & BusinessDevelopment, of SuperGen, +1-925-560-0100 x111, ; or GregGeissman, Director of Media Relations, of Noonan Russo, +1-619-814-3510,

Web site:

Ticker Symbol: (NASDAQ-NMS:SUPG)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. SuperGen to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
5. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
6. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
7. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
8. Elixir Pharmaceuticals Announces Clinical Data at American Diabetes Association Conference Highlighting Ability of Glufast to Maintain Glycemic Control in Patients with Type 2 Diabetes
9. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
10. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
11. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
Post Your Comments:
(Date:12/1/2015)... 1, 2015 --> ... report "Nucleic Acid Labeling Market by Product (Reagents & ... Primer, In Vitro Transcription, Reverse Transcription, End Labeling), by ... The global market is expected to reach USD 1,925.7 ... growing at a CAGR of 8.65%. Browse ...
(Date:12/1/2015)... Russia has always been a country of choice for ... Europe in 2015 were tested in phase II-III ... has always been a country of choice for global multi-center phase ... in 2015 were tested in phase II-III clinical trials ... always been a country of choice for global multi-center phase III clinical ...
(Date:12/1/2015)... Dec. 1, 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), ... chronic pain, announced today that the company will present at ... December 1-3 at the Luxe Sunset Boulevard Hotel in ... CEO of Relmada Therapeutics, will present on Thursday, December 3, ... . Please register at least 10 minutes prior ...
Breaking Medicine Technology:
(Date:12/1/2015)... , ... December 01, 2015 , ... According to an ... groups has filed a discrimination claim against the U.S. Department of Health and Human ... Affordable Care Act (ACA) plans are breaking the clause in the law prohibiting the ...
(Date:12/1/2015)... ... December 01, 2015 , ... Califia Farms , one ... its iconic bottle has won top honors in Beverage World Magazine’s Global Packaging Design ... announced that it has been selected as a 2015 U.S.A. Taste Champion in the ...
(Date:12/1/2015)... ... , ... Growth in medical payments per workers’ compensation claim in Louisiana slowed ... nonhospital care, according to a recent study by the Workers Compensation Research Institute (WCRI). ... medical payments per claim with more than seven days of lost time continued to ...
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS today announced ... Bridge Business Awards under the New Products and Services category for its innovative ... sample management software that helps labs organize data and track samples with ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic foot wounds ... Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a health care ... to diseases of the diabetic foot. The American Board of Multiple Specialties ...
Breaking Medicine News(10 mins):